European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 289-296 , March 2008

Carcinoid syndrome

,Accepted 20 July 2007.

References 

  1. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;858–867
  2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813–829
  3. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1:238–239
  4. Ramage JK, Catnach SM, Williams R. Overview: the management of metastatic carcinoid tumors. Liver Transpl Surg. 1995;1:107–110
  5. Bell HK, Poston GJ, Vora J, Wilson NJE. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152:71–75
  6. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol. 2004;99:2466–2478
  7. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities. Circulation. 1988;77:264–269
  8. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterisation and echocardiography. Circulation. 1995;92:790–795
  9. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–1196
  10. Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112:3320–3327
  11. Connolly HM, Pellikka PA. Carcinoid heart disease. Curr Cardiol Rep. 2006;8:96–101
  12. Thatipelli MR, Uber PA, Mehra MR. Isolated tricuspid stenosis and heart failure: a focus on carcinoid heart disease. Congest Heart Fail. 2003;9:294–296
  13. Quaedvlieg PF, Lamers CB, Taal BG. Carcinoid heart disease: an update. Scand J Gastroenterol Suppl. 2002;236:66–71
  14. Meijer WC, van Veldhuisen DJ, Kema IP, et al. Cardiovascular abnormalities in patients with a carcinoid syndrome. Neth J Med. 2002;60:10–16
  15. Di Luzio S, Rigolin VH. Carcinoid heart disease. Curr Treat Options Cardiovasc Med. 2000;2:399–406
  16. Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77:139–147
  17. Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation. 2001;104:136–140
  18. Connolly HM, Schaff HV, Mullany CJ, et al. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodelling. Circulation. 2002;106:151–156
  19. Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995;75:485–488
  20. Connolly HM, Nishimura RA, Smith HC, et al. Outcomes of cardiac surgery for carcinoid disease. J Am Coll Cardiol. 1995;25:410–416
  21. Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications for endoscopic polypectomy for rectal carcinoids and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005;48:285–291
  22. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;96:2271–2277
  23. Kaltsas G, Rockall A, Papdogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151:15–27
  24. Schaefer JF, Vollmar J, Schick F, et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging – perfusion differences in malignant and benign lesions. Radiology. 2004;232:544–553
  25. Seemann MD, Meisatschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res. 2006;11:58–65
  26. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of neuroendocrine tumors. N Engl J Med. 1990;323:1246–1249
  27. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results. Ann N Y Acad Sci. 1994;733:416–424
  28. Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-d-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994;131:577–581
  29. Savelli G, Lucignani G, Seregni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25:445–449
  30. Reisine T, Bell G. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427–442
  31. Bousquet C, Guillermet J, Vernejoul F, et al. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004;36(S1):S2–S7
  32. Hofland LJ, lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12(S2):S31–S36
  33. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with specific antibodies. Gut. 2002;50:52–60
  34. Hashemi SH, Benjegard SA, Ahlman H, et al. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours. Br J Surg. 2003;90:549–554
  35. Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/HYNAC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318–1325
  36. Gabriel M, Decristoforo C, Maina T, et al. 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an interpatient comparison of two novel technetium-99m labelled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm. 2004;19:73–79
  37. Forster GJ, Engelbach MJ, Brockmann JJ, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743–1750
  38. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet. 1998;351:417–418
  39. Hoefnagel CA, Lewington VJ. MIBG therapy. In:  Murray IPC,  Ell PJ editor. Nuclear medicine. vol. 2:Edinburgh: Churchill Livingstone; 1994;p. 851–864
  40. Pathirana AA, Vinjamuri S, Byrne C, et al. 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. Eur J Surg Oncol. 2001;27:404–408
  41. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902
  42. Eriksson B, Bergstrom M, Orlefors H, et al. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000;44:68–76
  43. Sundin A, Eriksson B, Bergstrom M, et al. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:246–257
  44. Eriksson B, Bergstrom M, Sundin A, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci. 2002;970:159–169
  45. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392–3400
  46. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–221
  47. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373–380
  48. Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728–734
  49. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001;12(2):S41–S45
  50. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-d-Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–48
  51. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000;190:432–445
  52. Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39–46
  53. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12:321–342
  54. Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001;87:447–452
  55. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170–175
  56. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005;241:776–783
  57. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–1063
  58. el Rassi ZS, Ferdinand L, Mohsine RM, et al. Primary and secondary liver endocrine tumors: clinical presentation, surgical approach and outcome. Hepatogastroenterology. 2002;49:1340–1346
  59. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37
  60. Knox CD, Feurer ID, Wise PE, et al. Survival and functional quality of life after resection for hepatic carcinoid metastases. J Gastrointest Surg. 2004;8:653–659
  61. Soreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg. 2000;24:1431–1436
  62. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677–682
  63. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  64. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954–962
  65. Gulec SA, Mountcastle TS, Frey D, et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg. 2002;68:667–671
  66. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer. 1995;76:501–509
  67. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8–12
  68. Hellmann P, Ladjevardis S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–1056
  69. Dick EA, Joarder R, de Jode M, et al. MR-guided laser thermal ablation of primary and secondary liver tumours. Clin Radiol. 2003;58:112–120
  70. Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine symptoms. Am J Roentgenol. 2003;181:1005–1010
  71. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003;10:463–468
  72. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases – the Middlesex experience. Abdom Imaging. 2005;30:435–441
  73. Navarra G, Ayav A, Weber JC, et al. Short- and long-term results of intraoperative radiofrequency ablation of liver metastases.
  74. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005;28:409–421
  75. Jensen EH, Kvols L, McLaughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14:1416–1423
  76. Hirai I, Kimura W, Fuse A, et al. Surgical management for metastatic liver tumors. Hepatogastroenterology. 2006;53:757–763
  77. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–1004
  78. Veenendaal LM, Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006;4:35
  79. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572–581
  80. Hodul P, Malafa M, Choi J, Kvols L. The role of cytoreductive surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006;13:61–71
  81. Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891–898
  82. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005;137:411–416
  83. Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. N Y Acad Sci. 1994;733:507–514
  84. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225:347–354
  85. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg. 1997;225:355–364
  86. Fernandez JA, Robles R, Marin C, et al. Role of liver transplantation in the management of metastatic neuroendocrine tumors. Transplant Proc. 2003;35:1832–1833
  87. Ahlman H, Friman S, Cahlin C, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265–269
  88. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8:208–212
  89. Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006;12:1089–1096
  90. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–456
  91. Knox CD, Anderson CD, Lamps LW, et al. Long-term survival after resection for primary hepatic carcinoid tumor. Ann Surg Oncol. 2003;10:1171–1175
  92. Fenwick SW, Wyatt JI, Toogood GJ, Lodge JP. Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg. 2004;239:210–219
  93. Schell SR, Camp ER, Caridi JG, Hawkins IF. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg. 2002;6:664–670
  94. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–1602
  95. Meij V, Zuetenhorst JM, van Hillegersberg R, et al. Local treatment in unresectable hepatic metastases of carcinoid tumors: experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol. 2005;3:75
  96. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13:72–78
  97. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000;12:151–157
  98. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136–140
  99. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion. 2003;68:94–101
  100. Fiorentini G, Rossi S, Bonechi F, et al. Intra-arterial chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004;16:293–297
  101. Dong XD, Yin X, Zeh HJ, et al. Long-term outcome in patients with liver metastases from neuroendocrine tumors treated with chemoembolization. [abstract 4167] Proc Am Soc Clin Oncol Annu Meet. 2005;23:349S
  102. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. 2003;9:261–267
  103. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastrointestinal system. Ann Oncol. 2004;15:966–973
  104. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–606
  105. Filosso PL, Ruffini E, Oliaro A, et al. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002;21:913–917
  106. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther. 2003;17:437–444
  107. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151:107–112
  108. Woltering E, Mamikunian PM, Zeitz S, et al. Octreotide acetate (LAR) dose effect on plasma octreotide levels: impact on neuroendocrine tumor management. Proc Am Soc Clin Oncol Annu Meet. 2005;23:235S;[abstract 3177]
  109. Fykse V, Sandvik AK, Qvigstad G, et al. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol. 2004;39:621–628
  110. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998;93:1468–1471
  111. Wymenga ANM, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17:1111–1117
  112. Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127–1130
  113. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–3281
  114. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23:412–415
  115. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–776
  116. Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol. 2000;53:755–758
  117. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol. 2002;79:180–187
  118. Bondanelli M, Ambrosio MR, Zatelli MC, et al. Regression of liver metastases of occult carcinoid tumour with slow release lanreotide therapy. World J Gastroenterol. 2005;11:2041–2044
  119. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001;12:1383–1391
  120. Taal BG, Hoefnagel C, Boot H, et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol. 2000;11:1437–1443
  121. Hoefnagel CA, Taal BG, Sivro F, et al. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun. 2000;21:755–761
  122. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytomas, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol. 2001;55:47–60
  123. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer. 2003;89:1383–1388
  124. Sywak MS, Pasieka JL, McEwan A, et al. 131I-meta-iodobenzylguanidine in the management of midgut carcinoid tumors. World J Surg. 2004;28:1157–1162
  125. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004;101:1987–1993
  126. van Eijck CHJ. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues. Br J Surg. 2005;92:1333–1334
  127. Slooter GD, Breeman WA, Marquet RL, et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer. 1999;81:767–771
  128. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art perspectives. Q J Nucl Med. 2000;44:88–95
  129. Meyers MO, Anthony LB, McCarthy KE, et al. High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J. 2000;93:809–811
  130. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44:1–6
  131. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–945
  132. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–616
  133. Valkema R, Kvols LK, Pawels S, et al. Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA, Tyr3]octreotide: toxicity and efficacy of 4-cycle and single-cycle regimens. [abstract 3046] Proc Am Soc Clin Oncol Annu Meet. 2004;23:206
  134. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762
  135. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabelled somatostatin analogs. J Nucl Med. 2005;46:62S–66S
  136. Davi MV, Bodei L, Francia G, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest. 2006;29:563–567
  137. Bajetta E, Bichisao E, Artale S, et al. New clinical trials for the treatment of neuroendocrine tumors. Q J Nucl Med. 2000;44:96–101
  138. Kaltsas GA, Mukherjee JJ, Isidori A, et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol. 2002;57:169–183
  139. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12(S2):S111–S114
  140. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion. 2000;62(S1):73–78
  141. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Anticancer Res. 2001;21:4087–4090
  142. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated carcinoid tumours. Br J Surg. 2003;90:687–693
  143. Hopfner M, Sutter AP, Huether A, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer. 2004;4:23
  144. Zuetenhorst JM, Valdes Olmos RA, Muller M, et al. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer. 2004;11:553–561
  145. Pape UF, Wiedenmann B. Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev. 2003;29:565–569
  146. Stuart K, Levy DE, Anderson T, et al. Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2004;22:75–81
  147. Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004;44:213–220
  148. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubacin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol. 2005;23:4897–4904
  149. Fine RL, Fogelman DR, Schreibman SM, et al. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. [abstract 4216] Proc Am Soc Clin Oncol Annu Meet. 2005;23:361S
  150. Ansell SM, Pitot HC, Burch PA, et al. A phase II study of high-dose paclitaxel with advanced neuroendocrine tumors. Cancer. 2001;91:1543–1548
  151. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004;22:353–359
  152. Kegel T, Grothe A, Jordan M, et al. Paclitaxel, carboplatin and etoposid (TCE) in the treatment of advanced neuroendocrine tumours. [abstract 4263] Proc Am Soc Clin Oncol Annu Meet. 2005;23:373S
  153. Miranda FT, Spigel DR, Hainsworth JD, et al. Paclitaxel/carboplatin/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: a Minnie Pearl Cancer Network phase II trial. [abstract 4058] Proc Am Soc Clin Oncol Annu Meet. 2005;23:322S
  154. Hopfner M, Sutter AP, Berst B, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer. 2003;89:1766–1775
  155. Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors. [abstract 4008] Proc Am Soc Clin Oncol Annu Meet. 2005;23:310S
  156. Hobday TJ, Mahoney M, Erlichman C, et al. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II Consortium (P2C) study. [abstract 4084] Proc Am Soc Clin Oncol Annu Meet. 2005;23:328S
  157. Yao JC, Charnsangavej S, Faria SC, et al. Rapid decrease in blood flow, blood volume and vascular permeability in carcinoid patients treated with bezacizumab. [abstract 3013] Proc Am Soc Clin Oncol Annu Meet. 2004;23:198
  158. Yao JC, Ng C, Hoff PM, et al. Improved progression free survival, and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. [abstract 4007] Proc Am Soc Clin Oncol Annu Meet. 2005;23:309S
  159. Mares JE, Worah S, Mathew SV, et al. Increased rate of hypertension among patients with advanced carcinoid treated with bevacizumab. [abstract 4087] Proc Am Soc Clin Oncol Annu Meet. 2005;23:329S
  160. Carr K, Yao JC, Rashid A, et al. A phase II trial of imatinib in patients with advanced carcinoid tumor. [abstract 4124] Proc Am Soc Clin Oncol Annu Meet. 2005;23:343
  161. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004;10:6111–6118
  162. Duran I, Le L, Saltman D, et al. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas. [abstract 3096] Proc Am Soc Clin Oncol Annu Meet. 2005;23:215S
  163. Aaronson NK, Cull A, Kaasa S, Sprangers M. The EORTC modular approach to quality of life assessment in oncology. Int J Ment Health. 1994;23(2):75–96
  164. Shumaker SA, Naughton MJ. The international assessment of health-related quality of life: a theoretical perspective. In:  Schumaker SA,  Bernzon R editor. The international assessment of health-related quality of life: theory, translation, measurement and analysis. Oxford: Rapid Communications of Oxford; 1995;p. 3–10
  165. Larsson G, Haglund K, Von Essen L. Distress, quality of life and strategies to ‘keep a good mood’ in patients with carcinoid tumours: patient and staff perceptions. Eur J Cancer Care (Engl). 2003;12:46–57
  166. Larsson G, Sjoden PO, Oberg K, Eriksson B, Von Essen L. Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2001;40:825–831
  167. Larsson G, Sjoden PO, Oberg K, Von Essen L. Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Ann Oncol. 1999;10:1321–1327
  168. Larsson G, Von Essen L, Sjoden PO. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol. 1999;38:481–490
  169. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med. 1995;237:269–275
  170. Jones LE. Patient perceptions and experiences of fatigue with metastatic carcinoid disease. MSc thesis, University of Liverpool; 2005.
  171. Davies AHG, Friend L, Jones L, et al. Development of a disease-specific EORTC quality of life score questionnaire for patients with gastrointestinal tumours. Gut. 2005;
  172. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  173. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality of life assessment in cancer clinical trials. Recent Results Cancer Res. 1998;111:231–249
  174. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European organisation for research and treatment of cancer approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on quality of life. Qual Life Res. 1993;2(4):287–295
  175. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European organisation for research and treatment of cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res. 1998;7(4):291–300

PII: S0748-7983(07)00518-5

doi: 10.1016/j.ejso.2007.07.202

European Journal of Surgical Oncology
Volume 34, Issue 3 , Pages 289-296 , March 2008

Article Tools